Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi’s Message On Emerging Markets? Catch Us If You Can

This article was originally published in PharmAsia News

Executive Summary

Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?

You may also be interested in...

Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter

Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts